摘要
抗结核药物性肝损伤(anti-tuberculosis drug-induced liver injury,AT-DILI)是临床抗结核治疗中最常见、危害最大的不良反应。本文从AT-DILI的发生率、危险因素、分子机制和风险评估等方面阐述了AT-DILI的最新进展,希望通过深入研究抗结核药物性肝损伤的分子机制,给未来结核病个体化治疗和管理寻找重要突破口。
Anti-tuberculosis drug-induced liver injury(AT-DILI)is the leading adverse drug reaction during tuberculosis treatment.This review summarizes the latest information of incidence,risk factors,mechanism and prediction associated with AT-DILI.Better understanding of the mechanisms of AT-DILI may help to the individualized treatment and effective management of tuberculosis in the future.
作者
张锦欣
陈娟娟
彭劼
ZHANG Jin-xin;CHEN Juan-juan;PENG Jie(Infectious Diseases in Southern Hospital of Southern Medical University,Guangdong Guangzhou 510515,China)
出处
《新发传染病电子杂志》
2019年第3期173-176,共4页
Electronic Journal of Emerging Infectious Diseases
基金
国家自然科学基金(81572000)
广东省自然科学基金(2017A030310649,2018A030313571)
关键词
结核
抗结核药物性肝损伤
分子机制
Tuberculosis
Anti-tuberculosis drug-induced liver injury
Mechanism
